Case Study 2 – Medialis differentiated the Fentanyl Buccal Tablet within the Rapid Onset Opioid Class

The rapid onset opioid class was congested with three members, with little clear differentiation between them.

When considering that the BTcP market was still in need of building, this meant that several companies were competing for a relatively small number of patients.

Innovation

Medialis assessed the data and selected a systematic review and network meta analysis (mixed treatment meta analysis) to model expected performance of the client’s product against its competitors.

Asset Generation

Medialis completed the study and published it in a high impact factor pain journal.

Efficacy of Rapid-Onset Oral Fentanyl Formulations vs. Oral Morphine for Cancer-Related Breakthrough Pain: A Meta-Analysis of Comparative Trials.

Jandhyala R, Fullarton JR, Bennett MI.

J Pain Symptom Manage. 2013 Feb 1. doi:pii: S0885-3924(12)00815-9. 10.1016/j.jpainsymman.2012.09.009. [Epub ahead of print]

Communication

Medialis were able to carry out full salesforce training, and generate promotional slide deck and leave pieces.

Formal 1:1 online key opinion leader briefing was carried, as well as an advisory board on initial completion of the project to obtain feedback.

The following claims were generated:

  • This mixed-treatment analysis suggests that FBT, ODT, and OTFC might provide more efficacious treatment options than oral morphine for BTcP.